A meta-analysis reviewed the short-term efficacy and safety of interleukin-23 (IL-23) targeted drugs in the treatment of moderate to severe psoriasis.
The approval of ustekinumab in pediatric patients was based on data from a phase 3 open-label, single-arm study (CADMUS Junior).
The ECLIPSE study provides important new information to guide longer-term therapy choices among the newer biologic treatment options for psoriasis.
Combination treatment with methotrexate and narrowband ultraviolet light B provided marked improvement in patients with recalcitrant palmoplantar psoriasis.
Positive results were announced from a phase 3b study comparing bimekizumab (UCB) to secukinumab for the treatment of moderate to severe plaque psoriasis.
A 20% incremental dose regimen produces faster response in patients with psoriasis, without increasing the risk for adverse events in III-V skin types.
Wynzora is a combination of calcipotriene, a synthetic vitamin D3 analogue, and betamethasone dipropionate, a corticosteroid, which utilizes the Company’s proprietary PAD Technology platform enabling stability of both agents in an aqueous formulation.
Effectiveness of UST 90 mg at 52 and 104 weeks in psoriasis and its efficacy in patients previously treated with anti-IL17 drugs were evaluated.
Among patients with moderate to severe plaque psoriasis, treatment with mirikizumab (Lilly) was found to be noninferior to secukinumab (Cosentyx; Novartis).
A first clinical experience with brodalumab in an HIV-positive patient proves successful and may imply the utility of brodalumab in this patient group.